BRAF and melanoma: For instance, high serum levels of VEGF (more than 43 pg/ml) at baseline was associated with decreased overall survival in stage IV metastatic melanoma patients treated with ipilimumab [46], and serum CXCL8 levels correlated with melanoma proliferation and survival in 24 BRAF-mutant melanoma patients treated with MAPK inhibitors [47].